ViewRay, Inc. (NASDAQ:VRAY) is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.17 per share from $ 8.72 million in revenue.
For the full year, analysts predict revenues of $ 51.58 million, while looking forward to loss of $ 0.71 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 58.00 million ~ $ 95.00 million
Click Here For More Historical Outlooks Of ViewRay, Inc.
Previous Quarter Performance
ViewRay, Inc. unfold loss for the second quarter of $ 0.18 per share, from the revenue of $ 14.22 million. The consensus estimates are loss of $ 0.16 per share from $ 6.83 million in revenue. The bottom line results missed street analysts by $ 0.02 or 12.5 percent, at the same time, top line results outshined analysts by $ 7.39 million or 108.20 percent.
Stock Performance
Shares of ViewRay, Inc. traded up $ 0.04 or 1.33 percent on Wednesday, reaching $ 3.05 with volume of 454.70 thousand shares. ViewRay, Inc. has traded high as $ 3.10 and has cracked $ 3.00 on the downward trend
The closing price of $ 3.05, representing a 171.17 % increase from the 52 week low of $ 1.11 and a 38.32 % decrease over the 52 week high of $ 4.88.
The company has a market capital of $ 451.23 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
ViewRay, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.viewray.com
ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image-guided radiation therapy system to image and treat cancer patients.
